Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 18 and up

Using brain stimulation to reduce fatigue after a stroke

Official title: Home-based Post-stroke Fatigue Treatment Using Transcranial Direct Current Stimulation (tDCS)

Run by Weill Medical College of Cornell University · NCT05816603 · Data updated 2026-11-12

This study is testing whether a brain stimulation treatment can help reduce fatigue in people who have had a stroke.

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment24 (estimated)
SponsorWeill Medical College of Cornell University
Academic / other
Locations1 site (New York, New York)
StatusRecruiting
StartedMay 23, 2023
Main results expectedDecember 2027
Study endsDecember 2027
Registry record updatedFebruary 27, 2026
Trial IDNCT05816603 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults over 18 who are more than three months post-stroke and experience severe fatigue.

Probably not a fit

Patients with a history of seizures, severe depression, or significant cognitive impairment may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of transcranial direct current stimulation (tDCS) as a non-drug treatment for post-stroke fatigue. It involves a double-blind, sham-controlled, randomized design with 24 participants, where half will receive real stimulation and the other half will receive a placebo. The tDCS device will be applied daily for 20 minutes over a two-week period, with follow-up assessments to evaluate fatigue severity and neuroimaging to observe brain changes. The goal is to determine if this intervention can effectively reduce fatigue in stroke survivors.

Why it matters

Potential benefit: If successful, this approach could significantly alleviate fatigue in stroke survivors, improving their quality of life.

How similar studies have gone: Other studies using tDCS for various neurological conditions have shown promising results, suggesting potential for success in this novel application.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Male or female patients aged \>18 years
* Greater than 3 months from first hemorrhagic or ischemic stroke (subacute to chronic), confirmed through neuroimaging (CT or MRI).
* Fatigue severity score average \>4 (severe fatigue)
* Willingness to remain stable on pharmacologic therapy through the duration of the study.
* Availability of a caregiver, family member, or friend to be present during the administration of the tDCS intervention.

Exclusion Criteria:

* Metal in the head (except mouth) or implanted cranial or thoracic devices (i.e. pacemaker, DBS stimulator)
* History of seizure
* History of moderate to severe traumatic brain injury
* A score of 10 or more on the PHQ-9 or GAD-7 scale, suggestive of moderate to severe depression/anxiety.
* A score of less than 21 on the MoCA suggesting major neurocognitive disorder.
* Signs of skin rash, infection, or laceration in the supraorbital region where the tDCS will be applied.
* Inability to provide informed consent
* Other major neurological, medical, or psychiatric illnesses that could confound results in the opinion of the site investigator.

Where it's running

  • Weill Cornell Medicine, 525 E. 68th St, Baker Pavilion, F-2106
    New York, New York, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.